JP2013545779A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545779A5
JP2013545779A5 JP2013543710A JP2013543710A JP2013545779A5 JP 2013545779 A5 JP2013545779 A5 JP 2013545779A5 JP 2013543710 A JP2013543710 A JP 2013543710A JP 2013543710 A JP2013543710 A JP 2013543710A JP 2013545779 A5 JP2013545779 A5 JP 2013545779A5
Authority
JP
Japan
Prior art keywords
amino
imidazo
cyclopropyl
pyrazin
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013543710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545779A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/072591 external-priority patent/WO2012080236A1/en
Publication of JP2013545779A publication Critical patent/JP2013545779A/ja
Publication of JP2013545779A5 publication Critical patent/JP2013545779A5/ja
Pending legal-status Critical Current

Links

JP2013543710A 2010-12-17 2011-12-13 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン Pending JP2013545779A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP10195635.7 2010-12-17
EP10195635 2010-12-17
EP10195699 2010-12-17
EP10195699.3 2010-12-17
EP11170163.7 2011-06-16
EP11170163 2011-06-16
EP11170158.7 2011-06-16
EP11170158 2011-06-16
PCT/EP2011/072591 WO2012080236A1 (en) 2010-12-17 2011-12-13 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders

Publications (2)

Publication Number Publication Date
JP2013545779A JP2013545779A (ja) 2013-12-26
JP2013545779A5 true JP2013545779A5 (enExample) 2015-02-05

Family

ID=45218758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013543710A Pending JP2013545779A (ja) 2010-12-17 2011-12-13 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン

Country Status (6)

Country Link
US (1) US20140135319A1 (enExample)
EP (1) EP2651945A1 (enExample)
JP (1) JP2013545779A (enExample)
CN (1) CN103429592A (enExample)
CA (1) CA2821819A1 (enExample)
WO (1) WO2012080236A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100852A (ja) * 1984-09-28 1985-06-04 Hitachi Ltd 情報伝送方法
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
CA2889919C (en) 2012-11-16 2021-08-17 University Health Network Pyrazolopyrimidine compounds
SG11201600373YA (en) 2013-07-31 2016-02-26 Gilead Sciences Inc Syk inhibitors
EA029372B1 (ru) * 2013-11-15 2018-03-30 Юниверсити Хелс Нетуорк Пиразолопиримидиновые соединения
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
EP3105218B1 (en) 2014-02-13 2019-09-25 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Lsd1阻害剤としてのシクロプロピルアミン類
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
ES2966392T3 (es) 2015-04-17 2024-04-22 Crossfire Oncology Holding B V Biomarcadores pronósticos para quimioterapia inhibidora de TTK
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
TWI833686B (zh) 2016-04-22 2024-03-01 美商英塞特公司 Lsd1 抑制劑之調配物
TW201841916A (zh) * 2017-04-12 2018-12-01 美商麥珍塔治療學股份有限公司 芳香烴受體拮抗劑及其用途
US20190314407A1 (en) * 2017-10-31 2019-10-17 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
PT3792260T (pt) * 2018-05-08 2024-10-02 Nippon Shinyaku Co Ltd Compostos de azabenzimidazol e produtos farmacêuticos
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CN113301897A (zh) * 2018-10-17 2021-08-24 美真达治疗公司 用芳烃受体拮抗剂治疗癌症的方法
CA3161582A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
NZ538686A (en) * 2002-09-23 2008-01-31 Schering Corp Novel imidazopyrazines as cyclin dependent kinase inhibitors
NZ538685A (en) * 2002-09-23 2008-02-29 Schering Corp Imidazopyrazines as cyclin dependent kinase inhibitors
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
JP2009507843A (ja) * 2005-09-09 2009-02-26 シェーリング コーポレイション アザ縮合サイクリン依存性キナーゼ阻害剤
US20070117804A1 (en) 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
TW200803863A (en) * 2005-11-10 2008-01-16 Schering Corp Method for inhibiting protein kinases
EP2029605A1 (en) 2006-06-06 2009-03-04 Schering Corporation Imidazopyrazines as protein kinase inhibitors
US8268809B2 (en) * 2006-09-05 2012-09-18 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
EP2079746A2 (en) 2006-11-08 2009-07-22 Schering Corporation Imidazopyrazines as protein kinase inhibitors
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
MX2010002115A (es) * 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
JP6168773B2 (ja) * 2009-04-29 2017-07-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換イミダゾキノキサリン
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
JP5728683B2 (ja) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
WO2011113862A1 (en) * 2010-03-18 2011-09-22 Bayer Pharma Aktiengesellschaft Imidazopyrazines
JP5824040B2 (ja) * 2010-06-01 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換イミダゾピラジン
EP2651947B1 (en) * 2010-12-17 2014-12-10 Bayer Intellectual Property GmbH 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CA2821817A1 (en) * 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP2013545776A (ja) * 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン

Similar Documents

Publication Publication Date Title
JP2013545779A5 (enExample)
JP2013515729A5 (enExample)
HRP20201337T1 (hr) Inhibitori lizin-specifične demetilaze-1
JP2013537174A5 (enExample)
JP2016523911A5 (enExample)
RU2507204C2 (ru) Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона
CN111601593B (zh) P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
HRP20240994T1 (hr) Spoj inhibitora jak i njegova uporaba
HRP20251479T1 (hr) Pesticidno aktivni kondenzirani biciklički heteroaromatski spojevi
SI3183247T1 (en) Aminopyrimidinyl compounds as inhibitors of JAK
JP2019523233A5 (enExample)
JP2006520805A5 (enExample)
JP2019504821A5 (enExample)
RU2016124176A (ru) Композиции тетрагидрохинолинов в качестве ингибиторов бромодомена вет
JP2011520908A5 (enExample)
HRP20160360T1 (hr) Supstituirani imidazopiridazini
JP2016528298A5 (enExample)
JP2012532931A5 (enExample)
JP2014521711A5 (enExample)
JP2013523884A5 (enExample)
RU2015152576A (ru) Производные индолин-2-она или пирролопиридин/пиримидин-2-она
JP2012501312A5 (enExample)
JP2011506417A5 (enExample)
RU2015105249A (ru) Ингибиторы mtor киназы для онкологических показаний и заболеваний, связанных с mtor/pi3k/akt путем метаболизма
JP2014522855A5 (enExample)